We reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Under the leadership of Chief Executive Officer Joseph Jimenez, the Executive Committee of Novartis (ECN) is responsible for overseeing the business operations of Group companies. ECN members are chosen by the Board of Directors.
To report an adverse event or any drug related issues concerning Novartis medicianal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event. Fax: 002 02 26031702. E-mail: [email protected]
For safety labels, please click here and follow the below steps:
Enter the name of the product in the search field
Select the result “Human medicine European public assessment report (EPAR)”
In product information section, click the link “EPAR- product information’ to download the last updated section of the EU SmPC